What Happened
- Researchers at IIT Bombay, led by Prof. Ashutosh Kumar (Department of Biosciences and Bioengineering), in collaboration with Prof. Vetriselvan Subramaniyan of Sunway University, Malaysia, have demonstrated that tracking how antibiotics accumulate in the outer membranes of liver cells can serve as an early predictor of drug-induced liver injury (DILI).
- The team built artificial membranes that closely resemble actual liver cell (hepatocyte) membranes and tested antibiotic behaviour using advanced biophysical techniques — Dynamic Light Scattering (DLS) and Cryo-Transmission Electron Microscopy (cryo-TEM).
- The key finding: the cell membrane — not just a drug's chemical potency — is a critical site where toxicity risk begins to emerge; drugs that accumulate more aggressively in the membrane lipid layer show a higher risk of liver damage.
- This approach allows researchers to flag high-risk drug candidates at the laboratory stage, before human trials, reducing costly late-stage drug development failures.
- The methodology is relatively fast and scalable, making it suitable for integration into early-stage pharmaceutical screening pipelines.
Static Topic Bridges
Drug-Induced Liver Injury (DILI): A Major Drug Safety Challenge
Drug-Induced Liver Injury (DILI) is the leading cause of acute liver failure in many countries and a primary reason why drugs are withdrawn from the market after approval. The liver is the central organ for drug metabolism: most oral drugs pass through the liver before entering systemic circulation, making it uniquely vulnerable to toxic byproducts of drug breakdown.
- DILI is classified as intrinsic (dose-dependent, predictable — e.g., paracetamol overdose) or idiosyncratic (unpredictable, occurring even at therapeutic doses — the harder clinical problem).
- Antibiotics are the drug class most frequently associated with idiosyncratic DILI.
- The liver metabolises drugs primarily via cytochrome P450 enzymes (Phase I), generating reactive metabolites that can damage hepatocytes.
- DILI can range from asymptomatic enzyme elevation to fulminant liver failure requiring transplantation.
- Drug safety agencies (US FDA, India's CDSCO) require extensive hepatotoxicity testing before approving new drugs.
Connection to this news: The IIT Bombay study directly addresses the early detection gap for DILI — most current tests detect liver toxicity only after cellular damage has begun. Membrane-based tracking offers a pre-damage signal.
Cell Membrane Biology: Structure and Drug Interactions
The cell membrane (plasma membrane) is a phospholipid bilayer that forms the outer boundary of every cell. Lipophilic (fat-soluble) drugs tend to partition into this bilayer rather than remain in the aqueous cytoplasm — this membrane accumulation is the mechanism the IIT study exploited. Changes in membrane fluidity, curvature, and integrity caused by drug accumulation are now understood as early indicators of cellular stress.
- The cell membrane consists of a phospholipid bilayer embedded with proteins, cholesterol, and glycolipids.
- Lipophilic drugs can insert between phospholipid tails, disrupting membrane structure — this is called membrane perturbation.
- Dynamic Light Scattering (DLS) measures particle size and distribution; Cryo-TEM provides nanoscale images of membrane structures.
- Liver cells (hepatocytes) have specific membrane compositions that can be replicated in vitro as "model membranes" — this is what the IIT team used.
- Earlier studies on membrane-drug interactions focused on antibacterial activity; this research repurposes the technique for safety prediction.
Connection to this news: By building artificial hepatocyte membranes and probing antibiotic behaviour within them, the IIT Bombay team has turned membrane biophysics into a practical drug safety tool — a significant methodological contribution.
India's Pharmaceutical Industry and Drug Development Pipeline
India is the world's largest producer of generic drugs by volume and the third largest by value, supplying approximately 20% of global generic medicine exports. However, India's pharmaceutical sector has historically been stronger in generic manufacturing than in original drug discovery. Research institutions like IITs are increasingly contributing to the pre-clinical and early-stage discovery pipeline.
- India's pharmaceutical market is valued at approximately $50 billion (2024), with exports of around $25 billion annually.
- India is a leading supplier of generic antibiotics globally, making antibiotic safety research directly relevant to domestic manufacturing.
- The government's Production Linked Incentive (PLI) scheme for pharmaceuticals aims to strengthen domestic API (Active Pharmaceutical Ingredient) manufacturing.
- CDSCO (Central Drugs Standard Control Organisation) is India's national drug regulator, overseeing clinical trials and drug approvals.
- IIT Bombay's research can feed into the early-stage safety screening pipeline used by Indian pharmaceutical companies.
Connection to this news: India's ambition to move up the pharmaceutical value chain — from generics to novel drug discovery — requires exactly the kind of early-stage safety innovation that the IIT Bombay study represents.
Antibiotic Resistance and Rational Antibiotic Use
The global antibiotic resistance crisis (antimicrobial resistance — AMR) is partly driven by overuse and inappropriate prescribing of antibiotics. Understanding the toxicological profiles of antibiotics more precisely — which is what the IIT study contributes to — can help clinicians choose safer antibiotics, guide dosing, and support rational use policies.
- AMR causes approximately 1.27 million deaths annually directly, and contributes to 4.95 million deaths globally (2019 data).
- India has one of the highest burdens of AMR, driven by high antibiotic consumption in both human health and agriculture.
- WHO's Global Action Plan on AMR calls for better surveillance, innovation in diagnostics, and rational prescribing.
- Knowing a drug's hepatotoxicity risk early can guide prescribers to prefer safer alternatives, especially in patients with liver disease.
Connection to this news: The IIT Bombay finding contributes to the AMR mitigation toolkit by enabling better characterisation of which antibiotics carry higher liver toxicity risks, supporting more informed prescribing.
Key Facts & Data
- Lead institution: IIT Bombay, Department of Biosciences and Bioengineering (Prof. Ashutosh Kumar)
- Collaborator: Sunway University, Malaysia (Prof. Vetriselvan Subramaniyan)
- Techniques used: Dynamic Light Scattering (DLS), Cryo-Transmission Electron Microscopy (cryo-TEM)
- Target: Artificial hepatocyte (liver cell) membranes — in vitro model
- Application: Early-stage pharmaceutical screening for hepatotoxicity potential
- DILI significance: Most common cause of acute liver failure; antibiotics are the most frequently implicated drug class
- India pharmaceutical exports: ~$25 billion annually; produces ~20% of global generic drugs by volume